Cytotoxicity News and Research

RSS

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Advances in drug screening

With the discovery of suitable molecular targets - cellular molecules along pathways crucial for sustaining the life of cancer cells - comes the perplexing dilemma of where to find the next therapeutics that will bind to and disable those targets.

23 Oct 2007

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech has announced results of in vitro cytotoxicity and in vivo pharmacokinetic studies conducted to evaluate the potential for combining its phase III anti-cancer antibody therapeutic, Proxinium, with first-line standard of care therapy for squamous cell carcinoma of the head & neck (SCCHN).

19 Apr 2007

Immunomedics presents results on novel immunotoxin for prostate and lung cancers

Immunomedics has presented at the 2007 Annual Meeting of the American Association for Cancer Research results on the in vitro and in vivo evaluation of a novel immunotoxin, Rap-hRS7, for the potential treatment of prostate and lung cancers.

18 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007

Cetuximab improves survival and slows progression of colorectal cancer

Research presented at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted, cetuximab.

17 Apr 2007

Dendrimer-encapsulated camptothecins

With an eye toward developing a delivery vehicle for anticancer agents that are poorly soluble in water, a research team at Boston University and the Research Triangle Institute (RTI) has developed a biocompatible dendrimer that wraps itself around water-insoluble drugs.

8 Jan 2007

Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems

In an attempt to create a single device that can image and treat tumors simultaneously, researchers at the University of Texas Southwestern Medical Center at Dallas have successfully melded magnetic iron nanoparticles, the anticancer drug doxorubicin, and a polymer tagged with a tumor-targeted molecule into a stable nanoparticle that accumulates inside human tumor cells.

6 Nov 2006

Reactive oxygen species in cancer cells

A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves.

12 Sep 2006

Scientists develop magnetic nanoparticles for medicine

Magnetic iron oxide nanoparticles have already proven their utility for imaging metastatic breast cancer lesions in sentinel lymph nodes, and numerous groups are attempting to use iron nanoparticles in other imaging applications.

5 Sep 2006

New methods for screening nanoparticles and interaction with human cells

Scientists have developed a screening method to examine how newly made nanoparticles - particles with dimensions on the order of billionths of a meter - interact with human cells following exposure for various times and doses.

21 Aug 2006

Txr1 gene that affects human cancer cells' sensitivity to chemotherapy

Gene that affects human cancer cells' sensitivity to chemotherapy - an important finding in the effort to increase the effectiveness of chemotherapy.

6 Aug 2006

Statins stop the replication of the hepatitis C virus

A new study shows that statins, which are typically used as anti-cholesterol medications, can inhibit the replication of the hepatitis C virus (HCV).

9 Jul 2006

New polymer-lipid hybrid nanoparticle

A novel combination of lipids, a negatively charged polymer, and the anticancer drug doxorubicin has yielded a new nanoparticle that can kill breast cancer cells that are normally resistant to this drug.

3 Jul 2006

Anti-cancer drugs based on platinum

Researchers at Virginia Commonwealth University's Massey Cancer Center have created a new platinum-based, anti-cancer agent able to overcome acquired drug resistance by first modifying the way it is absorbed into cancer cells and then attacking the DNA of those cancer cells.

6 Jan 2006

Children could be saved from neuroblastoma using antibody therapy

Combination of T cell, antibody to neuroblastoma cells and molecule that spurs T cell growth is designed to treat low initial tumor levels or small cancer cell populations that survive initial treatment, according to St. Jude.

22 Dec 2005

Nanobombs to eradicate cancer

University of Delaware researchers are opening a new front in the war on cancer, bringing to bear new nanotechnologies for cancer detection and treatment and introducing a unique nanobomb that can literally blow up breast cancer tumors.

13 Oct 2005

Smart nanocarrier technology will cancer treatment

A ‘smart’ nanocarrier technology developed by a team of researchers at the Institute of Bioengineering and Nanotechnology (IBN) is set to vastly improve the way cancer patients are treated.

22 Mar 2005

Researchers reduce the toxicity of water-soluble buckyballs by a factor of more than ten million

Researchers at Rice University's Center for Biological and Environmental Nanotechnology (CBEN) have demonstrated a simple way to reduce the toxicity of water-soluble buckyballs by a factor of more than ten million.

26 Sep 2004

Immunotherapy and chemotherapy combined, slows tumor progression and extends survival of patients with glioblastoma multiforme

Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have found that the combination of immunotherapy and chemotherapy significantly slowed tumor progression and extended survival of patients with glioblastoma multiforme (GBM).

17 Aug 2004